Compare
Gyre Therapeutics, Inc. vs UroGen Pharma Ltd. vs Xencor Inc vs Zevra Therapeutics, Inc.
| Latest fiscal year | Gyre Therapeutics, Inc. GYRE | UroGen Pharma Ltd. URGN | Xencor Inc XNCR | Zevra Therapeutics, Inc. ZVRA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $116.59M | $109.79M | $125.58M | $106.47M |
| Revenue growth (YoY) | +10.2% | +21.4% | +13.7% | +350.9% |
| Gross margin | n/a | 88.7% | n/a | n/a |
| Operating margin | 9.9% | -113.7% | -141.4% | -59.1% |
| Net margin | 8.5% | -139.8% | -73.2% | 78.2% |
| Net income | $9.88M | -$153.49M | -$91.92M | $83.23M |
| EPS (Diluted) | $0.02 | n/a | -$1.24 | $1.35 |
| Operating cash flow | $1.01M | -$162.44M | -$135.12M | -$1.60M |
| Free cash flow | -$180.0K | -$162.73M | -$138.27M | -$2.43M |
| Cash & equivalents | $37.07M | $110.75M | $54.07M | $62.41M |
| Total assets | $166.13M | $200.46M | $875.50M | $284.73M |
| Total liabilities | $23.85M | $305.93M | $239.91M | $130.07M |
| Shareholders' equity | $106.03M | -$105.47M | $635.59M | $154.66M |
| Return on year-end equity | 9.3% | n/a | -14.5% | 53.8% |
| Shares outstanding | 91.31M | 48.35M | 71.87M | 56.85M |
Revenue, most recent five fiscal years
| Fiscal year | Gyre Therapeutics, Inc. | UroGen Pharma Ltd. | Xencor Inc | Zevra Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $116.59M Ended 2025-12-31 | $109.79M Ended 2025-12-31 | $125.58M Ended 2025-12-31 | $106.47M Ended 2025-12-31 |
| 1 year earlier | $105.76M Ended 2024-12-31 | $90.40M Ended 2024-12-31 | $110.49M Ended 2024-12-31 | $23.61M Ended 2024-12-31 |
| 2 years earlier | $113.45M Ended 2023-12-31 | $82.71M Ended 2023-12-31 | $174.62M Ended 2023-12-31 | $27.46M Ended 2023-12-31 |
| 3 years earlier | $102.29M Ended 2022-12-31 | $64.36M Ended 2022-12-31 | $164.58M Ended 2022-12-31 | $10.16M Ended 2022-12-31 |
| 4 years earlier | $7.34M Ended 2021-12-31 | $48.04M Ended 2021-12-31 | $275.11M Ended 2021-12-31 | $28.65M Ended 2021-12-31 |